Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats

Menopause

Volumn 20, Issue 7, 2013, Pages 785-794

  Feigh, Michael ^a   Andreassen, Kim V ^a   Hjuler, Sara T ^a   Nielsen, Rasmus H ^a   Christiansen, Claus ^a   Henriksen, Kim ^a   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Insulin resistance; Menopause; Obesity; Ovariectomy; Salmon calcitonin

Indexed keywords

GLUCOSE; INSULIN; SALCATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; ENERGY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULINEMIA; LIPID DIET; NONHUMAN; OBESITY; OVARIECTOMY; RAT; TREATMENT DURATION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CALCITONIN; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; FASTING; FEMALE; GLUCOSE INTOLERANCE; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; OBESITY; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84879924058     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31827c58ab     Document Type: Article

References (54)

1. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-2411.
2. Brown LM, Clegg DJ. Central effects of estradiol in the regulation of food intake, body weight, and adiposity. J Steroid Biochem Mol Biol 2010;122:65-73.
3. Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas 2008;60:10-18.
4. Kaaja RJ. Metabolic syndrome and the menopause. Menopause Int 2008; 14:21-25.
5. Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 2004;6:180-185.
6. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
7. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115.
8. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther 2009;124:44-56.
9. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008;68:2131-2162.
10. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002; 34:504-508.
11. Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 2003;5:408-414.
12. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 2004; 20:55-60.
13. Lutz TA. Control of food intake and energy expenditure by amylintherapeutic implications. Int J Obes (Lond) 2009;33(suppl 1):S24-S27.
14. Wielinga PY, Lowenstein C, Muff S, Munz M, Woods SC, Lutz TA. Central amylin acts as an adiposity signal to control body weight and energy expenditure. Physiol Behav 2010;101:45-52.
15. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17:1736-1743.
16. Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 2007;293:E620-E627.
17. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31:1816-1823.
18. Trevaskis JL, Turek VF, Wittmer C, et al. Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. Endocrinology 2010;151:5657-5668.
19. Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM. Antiobesity effects of the A-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 2006;147:5855-5864.
20. Feigh M, Henriksen K, Andreassen KV, et al. A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. Diabetes Obes Metab 2011;13:911-920.
21. Lutz TA, Tschudy S, Rushing PA, Scharrer E. Amylin receptors mediate the anorectic action of salmon calcitonin (sCT). Peptides 2000; 21:233-238.
22. Perlow MJ, Freed WJ, Carman JS, Wyatt RJ. Calcitonin reduces feeding in man, monkey and rat. Pharmacol Biochem Behav 1980;12:609-612.
23. Del PE, Schade B, Riediger T, Lutz TA, Scharrer E. Effects of amylin and salmon calcitonin on feeding and drinking behavior in pygmy goats. Physiol Behav 2002;75:593-599.
24. Chelikani PK, Haver AC, Reidelberger RD. Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007;293: R1798-R1808.
25. Eiden S, Daniel C, Steinbrueck A, Schmidt I, Simon E. Salmon calcitoninVa potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents. J Physiol 2002;541(pt 3):1041-1048.
26. Wielinga PY, Alder B, Lutz TA. The acute effect of amylin and salmon calcitonin on energy expenditure. Physiol Behav 2007;91:212-217.
27. Giustina G, Cerudelli B, Cimino A, Rigosa C, Rotondi A, Radaeli E. Synthetic salmon calcitonin is not diabetogenic in patients with normal or impaired glucose metabolism. J Endocrinol Invest 1985;8:19-23.
28. Arbit E, Kidron M. Oral insulin: the rationale for this approach and current developments. J Diabetes Sci Technol 2009;3:562-567.
29. Karsdal MA, Henriksen K, Bay-Jensen AC, et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol 2011;51:460-471.
30. Gorres BK, Bomhoff GL, Gupte AA, Geiger PC. Altered estrogen receptor expression in skeletal muscle and adipose tissue of female rats fed a high-fat diet. J Appl Physiol 2011;110:1046-1053.
31. Lemieux C, Picard F, Labrie F, Richard D, Deshaies Y. The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes Res 2003;11:477-490.
32. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv 2005;2:191-197.
33. Buclin T, Cosma RM, Burckhardt P, Azria M, Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002;17:1478-1485.
34. Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004;19:1531-1538.
35. Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005;37:425-430.
36. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and A-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
37. Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 2001;25:1005-1011.
38. Potes CS, Lutz TA. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav 2010;100:511-518.
39. Na XL, Ezaki J, Sugiyama F, Cui HB, Ishimi Y. Isoflavone regulates lipid metabolism via expression of related genes in OVX rats fed on a high-fat diet. Biomed Environ Sci 2008;21:357-364.
40. Riediger T, Schmid HA, Lutz T, Simon E. Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. Am J Physiol Regul Integr Comp Physiol 2001;281:R1833-R1843.
41. Feigh M, Andreassen KV, Neutzsky-Wulff AV, et al. Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic A-cell area and function in Zucker diabetic fatty rats. Br J Pharmacol 2012; 167:151-163.
42. Riediger T, Schmid HA, Young AA, Simon E. Pharmacological characterisation of amylin-related peptides activating subfornical organ neurones. Brain Res 1999;837:161-168.
43. Ainslie DA, Morris MJ, Wittert G, Turnbull H, Proietto J, Thorburn AW. Estrogen deficiency causes central leptin insensitivity and increased hypothalamic neuropeptide Y. Int J Obes Relat Metab Disord 2001; 25:1680-1688.
44. Tulipano G, Vergoni AV, Soldi D, Muller EE, Cocchi D. Characterization of the resistance to the anorectic and endocrine effects of leptin in obesity-prone and obesity-resistant rats fed a high-fat diet. J Endocrinol 2004;183:289-298.
45. Mack CM, Smith PA, Athanacio JR, et al. Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes Obes Metab 2011;13:1105-1113.
46. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;26:784-790.
47. Bailey CJ, Ahmed-Sorour H. Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion. Diabetologia 1980;19:475-481.
48. Riant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 2009;150:2109-2117.
49. Moreno P, Acitores A, Gutierrez-Rojas I, et al. Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulinresistant and type 2 diabetic state. Peptides 2011;32:2077-2085.
50. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010; 59:1765-1770.
51. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-136.
52. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008;117:207-231.
53. Fisas A, Codony X, Romero G, et al. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 2006;148:973-983.
54. Pilon G, Ruzzin J, Rioux LE, et al. Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat-fed rats. Metabolism 2011;60:1122-1130.